Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Buy" by Brokerages

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) has received a consensus rating of "Buy" from the ten research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $30.25.

RCUS has been the topic of several research analyst reports. Bank of America lowered their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating on the stock in a report on Wednesday, February 19th. HC Wainwright raised shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $18.00 to $24.00 in a report on Wednesday, February 26th. Finally, Morgan Stanley decreased their price target on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th.

Arcus Biosciences Price Performance

Shares of RCUS traded up $0.07 during mid-day trading on Friday, reaching $9.06. The stock had a trading volume of 690,903 shares, compared to its average volume of 714,081. Arcus Biosciences has a 12 month low of $8.66 and a 12 month high of $19.11. The business has a fifty day moving average of $12.01 and a 200 day moving average of $14.76. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The firm has a market cap of $952.87 million, a price-to-earnings ratio of -2.88 and a beta of 1.36.

Remove Ads

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The firm had revenue of $36.00 million for the quarter, compared to the consensus estimate of $29.38 million. Equities analysts predict that Arcus Biosciences will post -3.15 EPS for the current year.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the business's stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the transaction, the chief financial officer now owns 60,138 shares in the company, valued at $902,070. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Yasunori Kaneko acquired 20,000 shares of the business's stock in a transaction on Thursday, February 27th. The shares were purchased at an average price of $10.06 per share, for a total transaction of $201,200.00. Following the transaction, the director now directly owns 28,400 shares of the company's stock, valued at approximately $285,704. The trade was a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC grew its holdings in shares of Arcus Biosciences by 59.8% in the third quarter. Jane Street Group LLC now owns 217,041 shares of the company's stock worth $3,319,000 after purchasing an additional 81,193 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Arcus Biosciences by 11.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company's stock worth $8,669,000 after purchasing an additional 59,536 shares during the last quarter. Parkman Healthcare Partners LLC grew its holdings in shares of Arcus Biosciences by 146.9% in the third quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company's stock worth $15,684,000 after purchasing an additional 610,219 shares during the last quarter. Barclays PLC grew its holdings in shares of Arcus Biosciences by 49.0% in the third quarter. Barclays PLC now owns 118,693 shares of the company's stock worth $1,816,000 after purchasing an additional 39,015 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Arcus Biosciences by 25.1% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company's stock worth $14,236,000 after purchasing an additional 186,750 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.